Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias

Bone Marrow Transplant. 2004 Nov;34(9):827-8. doi: 10.1038/sj.bmt.1704687.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Combined Modality Therapy
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Middle Aged
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Retrospective Studies
  • Stem Cell Transplantation*
  • Transplantation, Homologous

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate